Codexis and Nestlé Health Science Sign Purchase Agreement for CDX-7108 for Treating Exocrine Pancreatic Insufficiency (EPI)
Shots:
- As per the agreement, Codexis is eligible to receive an up front payment of $5M, potential milestone payments of up to $45M along with single-digit royalties based on net-sales. It may also receive an extra $5M if Nestlé Health Science chooses to go for an option to acquire 2 additional early-stage enzymes under development for EPI
- Nestlé Health Science will exclusively handle the ongoing development and commercialization of CDX-7108, covering all related costs
- Additionally, the companies have finished pre-clinical and P-I studies for CDX-7108 as per a previous agreement. Through this new agreement, Nestlé Health Science has the option to progress the compound further in the development process
Ref: Codexis | Image: Codexis
Related News:- Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
